Global Drugs for Non-small Cell Lung Cancer Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Drugs for Non-small Cell Lung Cancer Revenue
• 1.4 Market by Type
  • 1.4.1 Global Drugs for Non-small Cell Lung Cancer Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Radiofrequency Ablation (RFA)
  • 1.4.3 Radiation Therapy
  • 1.4.4 Chemotherapy
  • 1.4.5 Targeted Therapies
  • 1.4.6 Immunotherapy
• 1.5 Market by Application
  • 1.5.1 Global Drugs for Non-small Cell Lung Cancer Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Drugs for Non-small Cell Lung Cancer Market Perspective (2015-2026)
• 2.2 Global Drugs for Non-small Cell Lung Cancer Growth Trends by Regions
  • 2.2.1 Drugs for Non-small Cell Lung Cancer Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Drugs for Non-small Cell Lung Cancer Historic Market Share by Regions (2015-2020)
  • 2.2.3 Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Drugs for Non-small Cell Lung Cancer Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Drugs for Non-small Cell Lung Cancer Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Drugs for Non-small Cell Lung Cancer Players by Market Size
  • 3.1.1 Global Top Drugs for Non-small Cell Lung Cancer Players by Revenue (2015-2020)
  • 3.1.2 Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Drugs for Non-small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Drugs for Non-small Cell Lung Cancer Market Concentration Ratio
  • 3.2.1 Global Drugs for Non-small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Drugs for Non-small Cell Lung Cancer Revenue in 2019
• 3.3 Drugs for Non-small Cell Lung Cancer Key Players Head office and Area Served
• 3.4 Key Players Drugs for Non-small Cell Lung Cancer Product Solution and Service
• 3.5 Date of Enter into Drugs for Non-small Cell Lung Cancer Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Drugs for Non-small Cell Lung Cancer Historic Market Size by Type (2015-2020)
• 4.2 Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)
• 5.2 Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
• 6.2 Drugs for Non-small Cell Lung Cancer Key Players in North America (2019-2020)
• 6.3 North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
• 6.4 North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
• 7.2 Drugs for Non-small Cell Lung Cancer Key Players in Europe (2019-2020)
• 7.3 Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
• 7.4 Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

8 China

• 8.1 China Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
• 8.2 Drugs for Non-small Cell Lung Cancer Key Players in China (2019-2020)
• 8.3 China Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
• 8.4 China Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
• 9.2 Drugs for Non-small Cell Lung Cancer Key Players in Japan (2019-2020)
• 9.3 Japan Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
• 9.4 Japan Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
• 10.2 Drugs for Non-small Cell Lung Cancer Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
• 10.4 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

11 India

• 11.1 India Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
• 11.2 Drugs for Non-small Cell Lung Cancer Key Players in India (2019-2020)
• 11.3 India Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
• 11.4 India Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
• 12.2 Drugs for Non-small Cell Lung Cancer Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
• 12.4 Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Bristol-Myers Squibb
  • 13.1.1 Bristol-Myers Squibb Company Details
  • 13.1.2 Bristol-Myers Squibb Business Overview
  • 13.1.3 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Introduction
  • 13.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020))
  • 13.1.5 Bristol-Myers Squibb Recent Development
• 13.2 GlaxoSmithKline
  • 13.2.1 GlaxoSmithKline Company Details
  • 13.2.2 GlaxoSmithKline Business Overview
  • 13.2.3 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Introduction
  • 13.2.4 GlaxoSmithKline Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 13.2.5 GlaxoSmithKline Recent Development
• 13.3 Menarini
  • 13.3.1 Menarini Company Details
  • 13.3.2 Menarini Business Overview
  • 13.3.3 Menarini Drugs for Non-small Cell Lung Cancer Introduction
  • 13.3.4 Menarini Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 13.3.5 Menarini Recent Development
• 13.4 Sanofi
  • 13.4.1 Sanofi Company Details
  • 13.4.2 Sanofi Business Overview
  • 13.4.3 Sanofi Drugs for Non-small Cell Lung Cancer Introduction
  • 13.4.4 Sanofi Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 13.4.5 Sanofi Recent Development
• 13.5 Ziopharm Oncology
  • 13.5.1 Ziopharm Oncology Company Details
  • 13.5.2 Ziopharm Oncology Business Overview
  • 13.5.3 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Introduction
  • 13.5.4 Ziopharm Oncology Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 13.5.5 Ziopharm Oncology Recent Development
• 13.6 Alchemia
  • 13.6.1 Alchemia Company Details
  • 13.6.2 Alchemia Business Overview
  • 13.6.3 Alchemia Drugs for Non-small Cell Lung Cancer Introduction
  • 13.6.4 Alchemia Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 13.6.5 Alchemia Recent Development
• 13.7 Amgen
  • 13.7.1 Amgen Company Details
  • 13.7.2 Amgen Business Overview
  • 13.7.3 Amgen Drugs for Non-small Cell Lung Cancer Introduction
  • 13.7.4 Amgen Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 13.7.5 Amgen Recent Development
• 13.8 Apotex
  • 13.8.1 Apotex Company Details
  • 13.8.2 Apotex Business Overview
  • 13.8.3 Apotex Drugs for Non-small Cell Lung Cancer Introduction
  • 13.8.4 Apotex Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 13.8.5 Apotex Recent Development
• 13.9 BioMarin Pharmaceutical
  • 13.9.1 BioMarin Pharmaceutical Company Details
  • 13.9.2 BioMarin Pharmaceutical Business Overview
  • 13.9.3 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Introduction
  • 13.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 13.9.5 BioMarin Pharmaceutical Recent Development
• 13.10 CellAct Pharma
  • 13.10.1 CellAct Pharma Company Details
  • 13.10.2 CellAct Pharma Business Overview
  • 13.10.3 CellAct Pharma Drugs for Non-small Cell Lung Cancer Introduction
  • 13.10.4 CellAct Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 13.10.5 CellAct Pharma Recent Development
• 13.11 Cerulean Pharma
  • 10.11.1 Cerulean Pharma Company Details
  • 10.11.2 Cerulean Pharma Business Overview
  • 10.11.3 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Introduction
  • 10.11.4 Cerulean Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.11.5 Cerulean Pharma Recent Development
• 13.12 Cipla
  • 10.12.1 Cipla Company Details
  • 10.12.2 Cipla Business Overview
  • 10.12.3 Cipla Drugs for Non-small Cell Lung Cancer Introduction
  • 10.12.4 Cipla Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.12.5 Cipla Recent Development
• 13.13 Cornerstone Pharmaceuticals
  • 10.13.1 Cornerstone Pharmaceuticals Company Details
  • 10.13.2 Cornerstone Pharmaceuticals Business Overview
  • 10.13.3 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  • 10.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.13.5 Cornerstone Pharmaceuticals Recent Development
• 13.14 Curis
  • 10.14.1 Curis Company Details
  • 10.14.2 Curis Business Overview
  • 10.14.3 Curis Drugs for Non-small Cell Lung Cancer Introduction
  • 10.14.4 Curis Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.14.5 Curis Recent Development
• 13.15 CytRx
  • 10.15.1 CytRx Company Details
  • 10.15.2 CytRx Business Overview
  • 10.15.3 CytRx Drugs for Non-small Cell Lung Cancer Introduction
  • 10.15.4 CytRx Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.15.5 CytRx Recent Development
• 13.16 Eli Lilly
  • 10.16.1 Eli Lilly Company Details
  • 10.16.2 Eli Lilly Business Overview
  • 10.16.3 Eli Lilly Drugs for Non-small Cell Lung Cancer Introduction
  • 10.16.4 Eli Lilly Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.16.5 Eli Lilly Recent Development
• 13.17 Exelixis
  • 10.17.1 Exelixis Company Details
  • 10.17.2 Exelixis Business Overview
  • 10.17.3 Exelixis Drugs for Non-small Cell Lung Cancer Introduction
  • 10.17.4 Exelixis Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.17.5 Exelixis Recent Development
• 13.18 Fresenius Kabi
  • 10.18.1 Fresenius Kabi Company Details
  • 10.18.2 Fresenius Kabi Business Overview
  • 10.18.3 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Introduction
  • 10.18.4 Fresenius Kabi Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.18.5 Fresenius Kabi Recent Development
• 13.19 Genentech
  • 10.19.1 Genentech Company Details
  • 10.19.2 Genentech Business Overview
  • 10.19.3 Genentech Drugs for Non-small Cell Lung Cancer Introduction
  • 10.19.4 Genentech Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.19.5 Genentech Recent Development
• 13.20 Hikma Pharmaceuticals
  • 10.20.1 Hikma Pharmaceuticals Company Details
  • 10.20.2 Hikma Pharmaceuticals Business Overview
  • 10.20.3 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  • 10.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.20.5 Hikma Pharmaceuticals Recent Development
• 13.21 Hospira
  • 10.21.1 Hospira Company Details
  • 10.21.2 Hospira Business Overview
  • 10.21.3 Hospira Drugs for Non-small Cell Lung Cancer Introduction
  • 10.21.4 Hospira Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.21.5 Hospira Recent Development
• 13.22 Intas Pharmaceuticals
  • 10.22.1 Intas Pharmaceuticals Company Details
  • 10.22.2 Intas Pharmaceuticals Business Overview
  • 10.22.3 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  • 10.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.22.5 Intas Pharmaceuticals Recent Development
• 13.23 Karyopharm Therapeutics
  • 10.23.1 Karyopharm Therapeutics Company Details
  • 10.23.2 Karyopharm Therapeutics Business Overview
  • 10.23.3 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Introduction
  • 10.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.23.5 Karyopharm Therapeutics Recent Development
• 13.24 Kyowa Hakko Kirin
  • 10.24.1 Kyowa Hakko Kirin Company Details
  • 10.24.2 Kyowa Hakko Kirin Business Overview
  • 10.24.3 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Introduction
  • 10.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.24.5 Kyowa Hakko Kirin Recent Development
• 13.25 Ligand Pharmaceuticals
  • 10.25.1 Ligand Pharmaceuticals Company Details
  • 10.25.2 Ligand Pharmaceuticals Business Overview
  • 10.25.3 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  • 10.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  • 10.25.5 Ligand Pharmaceuticals Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer